MDSCs在脓毒症免疫抑制中的机制研究进展

doi:10.3760/cma.j.issn.1007-1245.2022.20.012

摘要/Abstract

摘要： 髓源性抑制细胞（MDSCs）是一群异质性、具有免疫抑制功能的未成熟髓样细胞。常在肿瘤免疫逃避机制的研究中被提及，除此之外，MDSCs还参与慢性炎症、感染、自身免疫性疾病、创伤等疾病的免疫调节。最近研究发现，MDSCs在脓毒症的发病机制中也起着关键作用。脓毒症是由于宿主对感染的免疫反应失调而导致危及生命的器官功能衰竭。有研究表明，与脓毒症幸存者相比，非幸存者的淋巴细胞显著减少。在脓毒症发病早期，MDSCs被招募到炎症部位，起到抑制炎症的作用；然而，如果MDSCs数量增多及其组织浸润持续存在，可导致显著的病理生理学改变（如淋巴细胞减少、宿主免疫抑制和免疫瘫痪），从而导致患者病情快速进展甚至愈后恶化。由此可见，MDSCs为脓毒症患者淋巴细胞减少提供了新的见解，现已成为脓毒症研究的一个新兴课题，并可能为脓毒症患者提供新的治疗靶点。本文综述了MDSCs的生物学特征及其在脓毒症免疫抑制中的作用机制，以期为脓毒症的基础研究和临床治疗提供新的靶点和思路。

关键词: 髓源性抑制细胞, 脓毒症, 免疫抑制, 靶向治疗

Abstract: Myeloid-derived suppressor cells (MDSCs) are a group of heterogeneous immature myeloid cells with immunosuppressive function. It is often mentioned in the study of tumor immune escape mechanism. In addition, MDSCs also participate in the immune regulation of chronic inflammation, infection, autoimmune diseases, trauma, and other diseases. Recent studies have found that MDSCs also play a key role in the pathogenesis of sepsis. Sepsis is a life-threatening organ failure caused by the imbalance of host immune response to infection. Studies have shown that compared with sepsis survivors, non-survivors have significantly reduced lymphocytes. In the early stage of sepsis, MDSCs are recruited to the inflammatory site to inhibit inflammation; however, if the number of MDSCs increases and its tissue infiltration persists, it can lead to significant pathophysiological changes (such as lymphopenia, host immunosuppression and immune paralysis), resulting in rapid progress or even worse of patients' condition. It can be seen that MDSCs provide new insights for lymphopenia in patients with sepsis, have become a new topic in sepsis research, and may provide new therapeutic targets for patients with sepsis. This article reviews the biological characteristics of MDSCs and its mechanism of action in sepsis immunosuppression, in order to provide new targets and ideas for the basic research and clinical treatment of sepsis.

Key words: Myeloid-derived suppressor cells, Sepsis, Immunosuppression, Targeted therapy

郝珊珊侯彦强. MDSCs在脓毒症免疫抑制中的机制研究进展[J]. 国际医药卫生导报, 2022, 28(20): 2872-2875.

Hao Shanshan, Hou Yanqiang. Progress in the mechanism of MDSCs in sepsis immunosuppression[J]. International Medicine and Health Guidance News, 2022, 28(20): 2872-2875.

参考文献

[1] Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity[J]. Nat Rev Immunol, 2021, 21(8): 485-498. DOI: 10.1038/s41577-020-00490-y.
[2] Schrijver IT, Théroude C, Roger T. Myeloid-derived suppressor cells in sepsis[J]. Front Immunol, 2019, 10: 327. DOI: 10.3389/fimmu.2019.00327.
[3] Ruan WS, Xu J, Lu YQ. Prospect of using deep learning for predicting differentiation of myeloid progenitor cells after sepsis[J]. Chin Med J (Engl), 2019, 132(15): 1862-1864. DOI: 10.1097/CM9.0000000000000349.
[4] Waeckel L, Venet F, Gossez M, et al. Delayed persistence of elevated monocytic MDSC associates with deleterious outcomes in septic shock: a retrospective cohort study[J]. Crit Care, 2020, 24(1): 132. DOI: 10.1186/s13054-020- 02857-y.
[5] Pawelec G, Verschoor CP, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: not only in tumor immunity[J]. Front Immunol, 2019, 10: 1099. DOI: 10.3389/fimmu.2019.01099.
[6] Nedeva C, Menassa J, Puthalakath H. Sepsis: inflammation is a necessary evil[J]. Front Cell Dev Biol, 2019, 7: 108. DOI: 10.3389/fcell.2019.00108.
[7] Groth C, Hu X, Weber R, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression[J]. Br J Cancer, 2019, 120(1): 16-25. DOI: 10.1038/s41416-018-0333-1.
[8] Liu Q, Wang Y, Zheng Q, et al. MicroRNA-150 inhibits myeloid-derived suppressor cells proliferation and function through negative regulation of ARG-1 in sepsis[J]. Life Sci, 2021, 278: 119626. DOI: 10.1016/j.lfs.2021.119626.
[9] Esher SK, Fidel PL, Noverr MC. Candida/Staphylococcal polymicrobial intra-abdominal infection: pathogenesis and perspectives for a novel form of trained innate immunity[J]. J Fungi (Basel), 2019, 5(2): 37. DOI: 10.3390/jof5020037.
[10] Huang M, Cai S, Su J. The pathogenesis of sepsis and potential therapeutic targets[J]. Int J Mol Sci, 2019, 20(21): 5376. DOI: 10.3390/ijms20215376.
[11] Rocheteau P, Chatre L, Briand D, et al. Sepsis induces long-term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapy[J]. Nat Commun, 2015, 6: 10145. DOI: 10.1038/ncomms10145.
[12] Paoli CJ, Reynolds MA, Sinha M, et al. Epidemiology and costs of sepsis in the United States-an analysis based on timing of diagnosis and severity level[J]. Crit Care Med, 2018, 46(12): 1889-1897. DOI: 10.1097/CCM.0000000000003342.
[13] Iwashyna TJ, Cooke CR, Wunsch H, et al. Population burden of long-term survivorship after severe sepsis in older Americans[J]. J Am Geriatr Soc, 2012, 60(6): 1070-1077. DOI: 10.1111/j.1532-5415.2012.03989.x.
[14] Gaieski DF, Edwards JM, Kallan MJ, et al. Benchmarking the incidence and mortality of severe sepsis in the United States[J]. Crit Care Med, 2013, 41(5): 1167-1174. DOI: 10.1097/CCM.0b013e31827c09f8.
[15] Ruan WS, Feng MX, Xu J, et al. Early activation of myeloid-derived suppressor cells participate in sepsis-induced immune suppression via PD-L1/PD-1 axis[J]. Front Immunol, 2020, 11: 1299. DOI: 10.3389/fimmu.2020.01299.
[16] Xu J, Peng Y, Yang M, et al. Increased levels of myeloid-derived suppressor cells in esophageal cancer patients is associated with the complication of sepsis[J]. Biomed Pharmacother, 2020, 125: 109864. DOI: 10.1016/j.biopha.2020.109864.
[17] Ma P, Beatty PL, McKolanis J, et al. Circulating myeloid derived suppressor cells (MDSC) that accumulate in premalignancy share phenotypic and functional characteristics with MDSC in cancer[J]. Front Immunol, 2019, 10: 1401. DOI: 10.3389/fimmu.2019.01401.
[18] Bergenfelz C, Leandersson K. The generation and identity of human myeloid-derived suppressor cells[J]. Front Oncol, 2020, 10: 109. DOI: 10.3389/fonc.2020.00109.
[19] Pillay J, Kamp VM, van Hoffen E, et al. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1[J]. J Clin Invest, 2012, 122(1): 327-336. DOI: 10.1172/JCI57990.
[20] Goldmann O, Beineke A, Medina E. Identification of a novel subset of myeloid-derived suppressor cells during chronic staphylococcal infection that resembles immature eosinophils[J]. J Infect Dis, 2017, 216(11): 1444-1451. DOI: 10.1093/infdis/jix494.
[21] Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy[J]. Nat Rev Immunol, 2013, 13(12): 862-874. DOI: 10.1038/nri3552.
[22] Hollen MK, Stortz JA, Darden D, et al. Myeloid-derived suppressor cell function and epigenetic expression evolves over time after surgical sepsis[J]. Crit Care, 2019, 23(1): 355. DOI: 10.1186/s13054-019-2628-x.
[23] Cassetta L, Baekkevold ES, Brandau S, et al. Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates[J]. Cancer Immunol Immunother, 2019, 68(4): 687-697. DOI: 10.1007/s00262-019-02302-2.
[24] MDSC-mediated mechanisms of immunosuppression[EB/OL]. https://www.rndsystems.com/pathways/mdsc- mediated-mechanisms-of-immunosuppression.
[25] Sangaletti S, Talarico G, Chiodoni C, et al. SPARC is a new myeloid-derived suppressor cell marker licensing suppressive activities[J]. Front Immunol, 2019, 10: 1369. DOI: 10.3389/fimmu.2019.01369.
[26] Bolognese AC, Sharma A, Yang WL, et al. Cold-inducible RNA-binding protein activates splenic T cells during sepsis in a TLR4-dependent manner[J]. Cell Mol Immunol, 2018, 15(1): 38-47. DOI: 10.1038/cmi.2016.43.
[27] Deng Q, Zhao T, Pan B, et al. Protective effect of tubastatin A in CLP-induced lethal sepsis[J]. Inflammation, 2018, 41(6): 2101-2109. DOI: 10.1007/s10753-018-0853-0.
[28] Dkhil MA, Al-Quraishy S, Moneim AEA. Ziziphus spina-christi leaf extract pretreatment inhibits liver and spleen injury in a mouse model of sepsis via anti-oxidant and anti-inflammatory effects[J]. Inflammopharmacology, 2018, 26(3): 779-791. DOI: 10.1007/s10787-017-0439-8.
[29] Gong Y, Zou L, Cen D, et al. Reduced expression of SARM in mouse spleen during polymicrobial sepsis[J]. Inflammation, 2016, 39(6): 1930-1938. DOI: 10.1007/s10753-016-0428-x.
[30] Sido JM, Yang X, Nagarkatti PS, et al. Δ9-tetrahydrocannabinol-mediated epigenetic modifications elicit myeloid-derived suppressor cell activation via STAT3/S100A8[J]. J Leukoc Biol, 2015, 97(4): 677-688. DOI: 10.1189/jlb.1A1014-479R.
[31] Xin J, Zhang Z, Su X, et al. Epigenetic component p66a modulates myeloid-derived suppressor cells by modifying STAT3[J]. J Immunol, 2017, 198(7): 2712-2720. DOI: 10.4049/jimmunol.1601712.
[32] Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function[J]. J Exp Med, 2006, 203(12): 2691-2702. DOI: 10.1084/jem.20061104.
[33] Meyer C, Sevko A, Ramacher M, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model[J]. Proc Natl Acad Sci U S A, 2011, 108(41): 17111-17116. DOI: 10.1073/pnas. 1108121108.
[34] Lin S, Wang J, Wang L, et al. Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC[J]. Am J Cancer Res, 2017, 7(1): 41-52.
[35] Chen HM, Ma G, Gildener-Leapman N, et al. Myeloid-derived suppressor cells as an immune parameter in patients with concurrent sunitinib and stereotactic body radiotherapy[J]. Clin Cancer Res, 2015, 21(18): 4073-4085. DOI: 10.1158/1078-0432.CCR-14- 2742.
[36] Sinha P, Okoro C, Foell D, et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells[J]. J Immunol, 2008, 181(7): 4666-4675. DOI: 10.4049/jimmunol.181.7.4666.
[37] Xue Y, Xu Y, Liu X, et al. Ferumoxytol attenuates the function of MDSCs to ameliorate LPS-induced immunosuppression in sepsis[J]. Nanoscale Res Lett, 2019, 14(1): 379. DOI: 10.1186/s11671-019-3209-2.